Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

The Lancet Infectious Diseases

Volumn 10, Issue 9, 2010, Pages 621-629

  Caminero, José A ^a,b   Sotgiu, Giovanni ^c   Zumla, Alimuddin ^d   Migliori, Giovanni Battista ^e  

^a Hospital General de Gran Canaria   (Spain)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c UNIVERSITY OF SASSARI   (Italy)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CARBAPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; THIOAMIDE; UNINDEXED DRUG; TUBERCULOSTATIC AGENT;

ANEMIA; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CLINICAL TRIAL; CROSS RESISTANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOXICITY; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTRIC INTOLERANCE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; INFECTION SENSITIVITY; INJECTION; LOW DRUG DOSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SHELF LIFE; STOMACH DISEASE; SUICIDAL IDEATION; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; CLASSIFICATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MULTIDRUG RESISTANCE; STANDARDS; TUBERCULOSIS;

AMIKACIN; ANTITUBERCULAR AGENTS; CAPREOMYCIN; DRUG RESISTANCE, MULTIPLE; ETHAMBUTOL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; HUMANS; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; TUBERCULOSIS;

EID: 77955872446     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70139-0     Document Type: Review

References (87)

1. Fox W, Ellard GA, Mitchison DA Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999, 3(suppl 2):231-279.
2. Caminero JA Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006, 10:829-837.
3. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004, 169:1103-1109.
4. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008, 359:563-574.
5. Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008, 14:1700-1706.
6. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis (Review). Cochrane Database Syst Rev 1: CD004795.
7. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
8. Caminero JA Extensively drug-resistant tuberculosis: is its definition correct?. Eur Respir J 2008, 32:1413-1415.
9. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005, 365:318-326.
10. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003, 348:119-128.
11. Tahaoglu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001, 345:170-174.
12. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006, 28:980-985.
13. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007, 11:1314-1320.
14. Johnston JC, Shahidi NC, Sadatsafavi M, FitzGerald JM Treatment outcomes of multidrug-reistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
15. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
16. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009, 33:871-881.
17. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008, 372:1403-1409.
18. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010, 51:6-14.
19. Raviglione M XDR-TB: entering the post-antibiotic era?. Int J Tuberc Lung Dis 2006, 10:1185-1187.
20. Guidelines of the programmatic management of drug-resistant tuberculosis WHO, (accessed July 30, 2010). http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf.
21. Guidelines for the programmatic management of drug-resistant tuberculosis WHO, (accessed July 30, 2010). http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
22. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs 2008, WHO, World Health Organization, (accessed July 30, 2010). http://www.who.int/tb/features_archive/xdr_mdr_policy_guidance/en/index.html.
23. Ling DI, Zwerling AA, Pai M GenoType MTBDR assays for the diagnosis of multidrug-reistant tuberculosis: a meta-analysis. Eur Respir J 2008, 32:1165-1174.
24. Caminero JA Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010, 14:382-390.
25. Caminero JA Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005, 25:928-936.
26. Key to evidence statements and grades of recommendations: SIGN 50-a guideline developer's handbook Scottish Intercollegiate Guidelines Network, (accessed on March 29, 2010). http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html.
27. Kim SJ Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005, 25:564-569.
28. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008, 12:129-145.
29. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007, 30:623-626.
30. Gagneux S, Burgos MV, DeRiemer K, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006, 2:e61.
31. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003, 47:3799-3805.
32. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263:227-230.
33. Warren RM, Streicher EM, van Pittius NC Gey, et al. The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis 2009, 89:199-202.
34. Van Deun A, Salim MA Hamid, Das AP Kumar, Bastian I, Portaels F Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004, 8:560-567.
35. Schaaf HS, Moll AP, Dheda K Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and managment in adults and children. Clin Chest Med 2009, 30:667-683.
36. Zhang Y, Telenti A Genetics of drug resistance in Mycobacterium tuberculosis. Molecular genetics of mycobacteria 2000, 235-254. ASM Press, Washington, DC. G.F. Hatfull, W.R. Jacobs (Eds.).
37. Williams DL, Spring L, Collins LA, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42:1853-1857.
38. Sintchenko V, Chew WK, Jelfs PJ, Gilbert GL Mutations in the rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology 1999, 31:257-260.
39. Uzun M, Erturan Z, Ang Ö Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002, 6:164-165.
40. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol 2002, 40:4435-4438.
41. Tousek J, Jancik E, Zelenka M, Jancikova-Máková M The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up. Tubercle 1967, 48:27-31.
42. Zierski M, Zachara A Late results in re-treatment of patients with pulmonary tuberculosis. Tubercle 1970, 51:172-177.
43. Somner AR, Brace AA Late results of treatment of chronic drug-resistant pulmonary tuberculosis. BMJ 1966, 1:775-778.
44. Caminero JA Likelihood of generating MDR-TB and XDR-TB under adequate national tuberculosis programme implementation. Int J Tuberc Lung Dis 2008, 12:869-877.
45. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance: Anti-tuberculosis drug resistance in the world, report No 4. World Health Organization 2008, 394:1-120. WHO.
46. Treatment of tuberculosis: guidelines for national programmes 2010, WHO, World Health Organization, (accessed July 30, 2010). http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf, fourth edition.
47. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. Eur Respir J 2008, 31:904-910.
48. Ginsburg AS, Grosset JH, Bishai WR Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
49. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003, 124:1476-1481.
50. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10:605-612.
51. Peloquin CA, Hadad DJ, Molino L Pereira Dutra, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008, 52:852-857.
52. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
53. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY Stepwise decrease in moxifloxacin susceptibility amongs clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resistance 2006, 12:7-11.
54. Cheng AFB, Yew WW, Chan EWC, Chin ML, Hui MMM, Chan RCY Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004, 48:596-601.
55. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006, 354:1352-1361.
56. Crowle AJ, Sbarbaro JA, Judson FN, Douvas GS, May MH Inhibition by streptomycin of tubercle bacilli within cultures human macrophages. Am Rev Respir Dis 1984, 130:839-844.
57. David HL, Laszlo A, Rastogi N Mode of action of antimycobacterial drugs. Acta Leprol 1989, 7(suppl 1):189-194.
58. Heifets L, Lindholm-Levy P Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M tuberculosis. Antimicrob Agents Chemother 1989, 33:1298-1301.
59. Shin S, Furin J, Alcántara F, et al. Hypokalemia among patients receiving treatment for multiddrug-resistant tuberculosis. Chest 2004, 125:974-980.
60. Tsukamura M Cross-resistance relationships between capreomycin, kanamycin, and viomycin resistances in tubercle bacilli from patients. Am Rev Respir Dis 1969, 99:780-782.
61. Tsukamura M, Mizuno S Cross-resistance relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis. J Gen Microbiol 1975, 88:269-274.
62. Tsukamura M, Mizuno S Studies on the cross-resistance of Mycobacterium tuberculosis, strain H37Rv, to aminoglycoside- and polypeptide-antibiotics. Microbiol Immunol 1980, 24:777-787.
63. Alangaden GJ, Kreiswirth BN, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42:1295-1297.
64. Krüüner A, Jureen P, Levina K, Ghebremichael S, Hoffner S Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:2971-2973.
65. Maus CE, Plikaytis BB, Shinnick TM Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:3192-3197.
66. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000, 97:9677-9682.
67. Mukherjee J, Socci A, Acha J, et al. The PIH guide to management of multidrug-resistant tuberculosis: international edition 2003, Partners in Health, Boston.
68. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002, 109:765-771.
69. Abate G, Hoffner SE, Thomsen VØ, Miörner H Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG. Eur J Clin Microbiol Infect Dis 2001, 20:329-333.
70. Lee H, Cho SN, Bang HE, et al. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Tuberc Lung Dis 2000, 4:441-447.
71. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT Pharmacokinetic evaluation of para-aminosalicylic acid granuels. Pharmacotherapy 1994, 14:40-46.
72. Jagannath C, Reddy MV, Kailasam S, O'Sullivan JF, Gangadharam PRJ Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995, 151:1083-1086.
73. Reddy VM, Nadahur G, Daneluzzi D, O'Sullivan JF, Gangadharam PRJ Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother 1996, 40:633-636.
74. Handbook of anti-tuberculosis agents 2008, Global Alliance for TB Drug Development, Elsevier, Amsterdam.
75. Hackbarth CJ, Ünsal I, Chambers HF Cloning and sequence analysis of a class A b-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1997, 41:1182-1185.
76. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005, 49:2816-2821.
77. Cynamon MH, Palmer GS In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983, 24:429-431.
78. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991, 99:1025-1026.
79. Cynamon MH, Klemens SP, Sharpe CA, Chase S Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43:1189-1191.
80. Dietze R, Hadad DJ, McGee B, et al. Early and extended bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008, 178:1180-1185.
81. Ntziora F, Falagas ME Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int J Tuberc Lung Dis 2007, 11:606-611.
82. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006, 58:701-704.
83. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009, 34:387-393.
84. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009, 64:388-391.
85. Watt B, Edwards JR, Rayner A, Grindey AJ, Harris G In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic schedule. Tuber Lung Dis 1992, 73:134-136.
86. Hugonnet J, Tremblay L, Boshoff HI, Barry CE, Blanchard JS Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323:1215-1218.
87. Elliott AM, Foster SD Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection. Tuber Lung Dis 1996, 77:27-29.